---
title: "Phibro Animal Health Corporation (PAHC.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/PAHC.US.md"
symbol: "PAHC.US"
name: "Phibro Animal Health Corporation"
industry: "Pharmaceuticals"
datetime: "2026-05-20T14:03:45.819Z"
locales:
  - [en](https://longbridge.com/en/quote/PAHC.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/PAHC.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/PAHC.US.md)
---

# Phibro Animal Health Corporation (PAHC.US)

## Company Overview

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Latin America and Canada, Europe, the Middle East, Africa, and the Asia Pacific. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal’s health and performance, food safety, and animal welfare; and engages in developing, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [www.pahc.com](https://www.pahc.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:15.000Z

**Overall: B (0.33)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 22 / 189 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Growth - Stocks whose main business is in the growth stage.
- **Scale**: Mid - The company has stable operation of a large-cap stock and the high return of a small-cap stock.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 25.98% |  |
| Net Profit YoY | 199.55% |  |
| P/B Ratio | 3.80 |  |
| Dividend Ratio | 1.42% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 1375143872.40 |  |
| Revenue | 1500043000.00 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 30.34% | A |
| Profit Margin | 6.35% | B |
| Gross Margin | 32.77% | C |
| Revenue YoY | 25.98% | A |
| Net Profit YoY | 199.55% | A |
| Total Assets YoY | 9.71% | B |
| Net Assets YoY | 36.03% | A |
| Cash Flow Margin | 69.44% | C |
| OCF YoY | 25.98% | A |
| Turnover | 1.09 | A |
| Gearing Ratio | 74.96% | E |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Phibro Animal Health Corporation",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "25.98%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "199.55%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "3.80",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "1.42%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "1375143872.40",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "1500043000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "30.34%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "6.35%",
          "rating": "B"
        },
        {
          "name": "Gross Margin",
          "value": "32.77%",
          "rating": "C"
        },
        {
          "name": "Revenue YoY",
          "value": "25.98%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "199.55%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "9.71%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "36.03%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "69.44%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "25.98%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "1.09",
          "rating": "A"
        },
        {
          "name": "Gearing Ratio",
          "value": "74.96%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 14.44 | 24/189 | 33.98 | 26.01 | 23.32 |
| PB | 3.80 | 130/189 | 6.28 | 5.34 | 4.44 |
| PS (TTM) | 0.92 | 30/189 | 1.42 | 1.18 | 0.99 |
| Dividend Yield | 1.42% | 26/189 | 1.61% | 1.21% | 0.93% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Cormedix (CRMD.US) | A | A | B | C | B | A |
| 02 | Eli Lilly (LLY.US) | A | A | B | D | B | B |
| 03 | ROCHE HOLDINGS AG (RHHVF.US) | A | B | B | D | B | B |
| 04 | Roche (RHHBY.US) | A | B | B | D | B | B |
| 05 | AstraZeneca (AZN.US) | A | B | C | D | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-14T04:00:00.000Z

Total Analysts: **5**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Overweight | 1 | 20% |
| Hold | 3 | 60% |
| Underweight | 1 | 20% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 34.81 |
| Highest Target | 62.00 |
| Lowest Target | 38.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/PAHC.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/PAHC.US/norm.md)
- [Related News](https://longbridge.com/en/quote/PAHC.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/PAHC.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**